{"title":"Chemistry, Biological Properties, and Bio-analysis of Tafamidis, a New Transthyretin Stabilizer: A Systematic Review.","authors":"Nikhil Agarwal, Sanjay Sharma, Jasira Sultan","doi":"10.2174/0118715257250153231011062855","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Cardiomyopathy is a global health crisis that affects people all over the world. Consequently, scientists felt compelled to look for and develop ever-more-powerful pharmaceuticals. For ATTR-CM, the only drug currently recommended by the European Society of Cardiology is Tafamidis.</p><p><strong>Objectives: </strong>The primary aim of this review article is to understand the chemistry, pharmacodynamic, pharmacokinetic, and bio-analytical methods available for Tafamidis.</p><p><strong>Methods: </strong>A systematic review of the existing resources was accomplished up to 2022, comprising existing studies forming the database covering the existing resources from Web of Science, ScienceDirect, and PubMed.</p><p><strong>Results: </strong>The review was based on a systematic review of all the existing studies used to formulate the database. The study also illustrated the PRISMA design that systematically analyses the prevalent resources.</p><p><strong>Conclusion: </strong>Minimal analytical techniques are observed for quantifying the Tafamidis and transthyretin kinetic stabiliser. Therapeutic, pharmacological, and analytical considerations for the novel drug Tafamidis are discussed in this review. Particular attention is paid to the many different analytical and bioanalytical methods currently available for estimating Tafamidis, and the need is highlighted to develop a straightforward, validated technique that meets green chemistry standards.</p>","PeriodicalId":93924,"journal":{"name":"Cardiovascular & hematological agents in medicinal chemistry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular & hematological agents in medicinal chemistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118715257250153231011062855","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Cardiomyopathy is a global health crisis that affects people all over the world. Consequently, scientists felt compelled to look for and develop ever-more-powerful pharmaceuticals. For ATTR-CM, the only drug currently recommended by the European Society of Cardiology is Tafamidis.
Objectives: The primary aim of this review article is to understand the chemistry, pharmacodynamic, pharmacokinetic, and bio-analytical methods available for Tafamidis.
Methods: A systematic review of the existing resources was accomplished up to 2022, comprising existing studies forming the database covering the existing resources from Web of Science, ScienceDirect, and PubMed.
Results: The review was based on a systematic review of all the existing studies used to formulate the database. The study also illustrated the PRISMA design that systematically analyses the prevalent resources.
Conclusion: Minimal analytical techniques are observed for quantifying the Tafamidis and transthyretin kinetic stabiliser. Therapeutic, pharmacological, and analytical considerations for the novel drug Tafamidis are discussed in this review. Particular attention is paid to the many different analytical and bioanalytical methods currently available for estimating Tafamidis, and the need is highlighted to develop a straightforward, validated technique that meets green chemistry standards.
背景:心肌病是影响全世界人民的全球性健康危机。因此，科学家们感到有必要寻找和开发更强大的药物。对于atr - cm，目前欧洲心脏病学会推荐的唯一药物是他法非底斯。目的:这篇综述文章的主要目的是了解Tafamidis可用的化学、药效学、药代动力学和生物分析方法。方法:对现有资源进行了系统的回顾，截至2022年，包括现有研究，形成了涵盖Web of Science、ScienceDirect和PubMed现有资源的数据库。结果:本综述是基于对所有现有研究的系统综述，这些研究用于建立数据库。该研究还说明了系统分析流行资源的PRISMA设计。结论:他法非底斯和甲状腺素动力学稳定剂的定量分析方法简便。本综述讨论了新型药物他法米底斯的治疗、药理学和分析方面的考虑。特别关注目前可用于估计Tafamidis的许多不同的分析和生物分析方法，并强调需要开发一种符合绿色化学标准的简单、有效的技术。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
